MK2 is a therapeutic target for high-risk multiple myeloma.

Gu, Chunyan; Cheng, Haibo; Yang, Hongbao; Bian, Yong; Wang, Yaohui; Zhang, Yifen; Pisano, Michael; Hu, Gang; Yang, Ye

Gu, Chunyan; Cheng, Haibo; Yang, Hongbao; Bian, Yong; Wang, Yaohui; Zhang, Yifen; Pisano, Michael; Hu, Gang; Yang, Ye.

Afiliación

Gu C; Department of Pathology, School of Medicine, University of Iowa, Iowa City, USA.
Cheng H; The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Yang H; China Pharmaceutical University, Nanjing, China.
Bian Y; Laboratory Animal Center, Nanjing University of Chinese Medicine, Nanjing, China.
Wang Y; Department of Pathology, The First Affiliated Hospital of Nanjing University of Chinese Medicine.
Zhang Y; Department of Pathology, The First Affiliated Hospital of Nanjing University of Chinese Medicine.
Pisano M; Department of Pathology, School of Medicine, University of Iowa, Iowa City, USA.
Hu G; School of Medicine and Life Sciences, Nanjing University of Chinese Medicine.
Yang Y; Nanjing University of Chinese Medicine, Nanjing, China.

Haematologica ; 106(6): 1774-1777, 2021 06 01.

Article en En | MEDLINE | ID: mdl-29567777

Asunto(s)

Mieloma Múltiple; Humanos; Péptidos y Proteínas de Señalización Intracelular; Mieloma Múltiple/tratamiento farmacológico; Mieloma Múltiple/genética; Proteínas Serina-Treonina Quinasas

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Haematologica Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google